Outcome for 105 patients with candidemia treated with amphotericin B was correlated with amphotericin B in vitro susceptibility results. Thirty-three patients had microbiologic failure, which was defined as persistence of Candida in the bloodstream despite §3 days of amphotericin B. Amphotericin B minimum inhibitory concentrations (MICs) were determined by the National Committee for Clinical Laboratory Standards methodology. After determination of MICs, the minimal lethal concentrations (MLCs) were determined. The isolates tested yielded a narrow range of amphotericin B MICs (0.06 -2 mg/mL); only 5% (5/105) exhibited MICs §1 mg/mL. The MLC range, on the other hand, was significantly broader (0.125 to ú16 mg/mL); 24% (25/105) exhibited MLCs §1 mg/mL. The strongest predictor for microbiologic failure was 48-h MLC (P õ .001), followed by 24-h MLC (P Å .03) and 48-h MIC (P Å .11). A resistant break point for amphotericin B of ú1 mg/ mL for MLC and §1 mg/mL for MIC could be inferred from this study.
Due to the recent introduction of new antifungal agents, to discriminate susceptible from resistant isolates [4] . Second, the study included candidemic patients, in whom the vascular physicians have more options in selecting antifungal therapy that best fits their patients. Unlike in vitro antibacterial suscepticatheters were not removed. Catheter retention is an independent factor for microbiologic failure in patients with candidebility testing, which has been useful in the selection of optimal antibacterial therapy, antifungal susceptibility testing has been mia [5] and therefore might have confounded the analysis. We have completed a prospective observational study of hampered by a number of limitations, including the lack of standardized methodology and the lack of correlation between candidemia [5] . The goal of the present study was to determine whether in vitro susceptibility results for Candida species corin vitro results and in vivo outcome. The National Committee for Clinical Laboratory Standards (NCCLS) has proposed stanrelated with patient outcome. We substituted RPMI medium with antibiotic medium 3 (AM3), both with and without suppledardized methodology for antifungal susceptibility testing and the tentative interpretive break points for the triazole agents mented glucose; this medium is more sensitive in the detection of amphotericin B -resistant isolates [6] . In addition, we ex- [1, 2] . The methodology remains to be validated for amphotericin B testing, however [1] .
cluded all patients with candidemia in whom the vascular catheters were not removed as part of therapy for candidemia. FiRex et al. [3] found no correlation between amphotericin B MIC and the outcome of patients with candidemia. Indeed, nally, since there is evidence that amphotericin B minimal lethal concentrations (MLCs) may predict in vivo resistance more cases of failure were seen among the patients infected with isolates for which MICs were low than among those inbetter than MICs [7] , we also assessed this parameter as a predictor of microbiologic outcome. fected with isolates for which MICs were high. This study had several limitations, however. First, the M-27P method used in that study [3] utilized RPMI medium, which is known to yield Methods a narrow range of MICs and therefore may have been unable
Isolates. One hundred five Candida isolates were obtained from the bloodstream of patients prospectively followed in a multicenter observational study of candidemia; all these patients 3  0  0  0  0  0  0  0  0  0  0  0  3  0  0.06  8  2  0  0  2  0  5  0  0  0  0  1  1 5  3  0.125  20  19  6  0  6  5  3  6  1  0  1  0  3 7  3 0  0.25  17  23  9  9  9  9  1  3  1  0  1  1  3 8  4 5  0 . 5  5  8  4  8  1  4  1  0  0  2  1  0  1 2  2 was 0.125 mg/mL at 24 h and 0.5 mg/mL at 48 h. The MIC 90
The MIC was defined as the lowest concentration of amphoteriwas 0.5 mg/mL at both 24 and 48 h. 
Distribution of amphotericin B MLCs determined in AM3
which corresponded to 0.1% of the control inoculum [8].
( 
respectively (P Å .11, ANOVA). It should be pointed out, isolates associated with microbiologic failure and those not associated with failure were 1.3 and 0.6 mg/mL, respectively however, that 100% (5/5) of isolates with 48-h MICs §1 mg/ mL were associated with failure, whereas only 28% (28/100) (P Å .03, ANOVA). Similarly, the geometric mean MLCs at 48 h for isolates associated with microbiologic failure and those of those with 48-h MICs õ1 mg/mL were associated with failure (P Å .003, Fisher's exact test) (table 3, figure 1) .
not associated with failure were 4.1 and 0.8 mg/mL, respectively (P õ .001, ANOVA did not predict microbiologic failure (P Å .08). The fact that the 48-h MLC was superior to the 24-h MLC in predicting failure was further demonstrated by assessing the microbiologic the 3 were associated with microbiologic failure. On the other outcome for the 7 patients infected with isolates for which the hand, 2 of the 3 isolates that exhibited MLC ú1 mg/mL by 48-h and 24-h MLC results were discordant (i.e., 48-h MLC AM3 but £1 mg/mL by AM3 with glucose were associated ú1 mg/mL but 24-h MLC £1 mg/mL); in each instance, the with failures.
48-h MLC correlated with outcome, while the 24-h MLC did not (table 4) . The specificity of a break-point MLC at 48 h of ú1 mg/mL Discussion for microbiologic failure was 94% (68/72), and the positive predictive value was 78% (14/18; table 3). These results are This is the first study to demonstrate a correlation between results of in vitro susceptibility testing to amphotericin B using acceptable for a disease syndrome such as candidemia, in which a significant percentage of bloodstream isolate organisms, even the standard method proposed by NCCLS and microbiologic outcome for patients with Candida fungemia. In this study, those resistant in vitro to the antifungal agent given, might sometimes resolve merely by removal of the vascular catheter. microbiologic failure was defined as either persistence of Candida in the bloodstream despite §3 days of amphotericin B A break-point MIC can also be inferred on the basis of our findings (figure 1). All 5 patients (100%) infected with isolates therapy or development of breakthrough Candida fungemia while receiving amphotericin B for at least 3 days for either exhibiting an amphotericin B MIC §1.0 mg/mL at 48 h were associated with microbiologic failure, compared with only 28% prophylactic or empiric purposes.
We found that the strongest predictor for microbiologic fail-(28/100) of those exhibiting MIC õ1.0 mg/mL (P Å .003; figure 1 ). In other words, a break-point MIC of §1.0 mg/ ure was the amphotericin B MLC determined at 48 h. Candida species isolated from patients who experienced microbiologic mL had a 100% (72/72) specificity and a 100% (5/5) positive predictive value for identifying microbiologic failure. The failure exhibited significantly higher amphotericin B MLCs (geometric mean, 4.1 mg/mL) than those isolated from patients break-point value of 1 mg/mL inferred by our data is biologically plausible, since the attainable peak serum level with a who responded to amphotericin B therapy (geometric mean, 0.8 mg/mL; P õ .001). The 24-h MLCs also predicted microbidaily dose of amphotericin B at 0.6 mg/kg is Ç1.4 mg/mL [9] . Our proposed break points sacrifice sensitivity: 58% (19/33) ologic failure, although to a lesser extent than 48-h MLCs (P Å .03).
and 85% (28/33) of isolates involved in microbiologic failure exhibited MLC õ1 mg/mL and MIC £1.0 mg/mL, respectively. MICs correlated less well with outcome than did MLCs. Candida species isolated from patients who experienced microThis finding underscores the importance of a variety of factors in addition to in vitro susceptibility data in determining therabiologic failure exhibited a geometric mean MIC at 48 h of 0.61 mg/mL, whereas those isolated from patients who responded to peutic response, such as host immune status, persistence of undrained focus of infection, and presence of foreign body. amphotericin B exhibited a geometric mean MIC of 0.31 mg/ mL (P Å .11). Since the MICs exhibited by all isolates at 24
The insensitivity of MIC in predicting outcome further stems from the inability of the standardized testing method to yield h were £0.5 mg/mL, the correlation of MIC with outcome was not apparent. a wide range of amphotericin B MICs; indeed, 92% (97/105) of isolates exhibited 48-h MICs that fell within a 4-fold range More relevant than overall correlation between results of in vitro testing and outcome, however, is the ability of these tests of dilutions (0.125 -0.5 mg/mL). This compression of the am-/ 9d3f$$fe09 12-05-97 11:54:21 jinfa UC: J Infect photericin B MIC range was a well-recognized limitation of the suggest that amphotericin B susceptibility testing may be par-NCCLS proposed standard for amphotericin B susceptibility ticularly useful for patients infected with non -C. albicans spetesting of yeasts when RPMI 1640 was used as the testing cies. If high in vitro MLCs are documented, alternative theramedium [4] . We found the same limitation when AM3 was peutic regimens should be contemplated. substituted for RPMI 1640.
Furthermore, we found that AM3 supplemented with 2%
